The Harvard Law School Forum on Corporate Governance https://corpgov.law.harvard.edu The leading online blog in the fields of corporate governance and financial regulation. Wed, 12 Aug 2026 13:32:25 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.9 https://corpgov.law.harvard.edu/wp-content/uploads/2024/02/cropped-photography-4-e1706898544564-1-32x32.png Shareholder Activism in Life Sciences: Risks, Responses, and Outlook – The Harvard Law School Forum on Corporate Governance https://corpgov.law.harvard.edu 32 32 Shareholder Activism in Life Sciences: Risks, Responses, and Outlook https://corpgov.law.harvard.edu/2026/03/11/shareholder-activism-in-life-sciences-risks-responses-and-outlook/?utm_source=rss&utm_medium=rss&utm_campaign=shareholder-activism-in-life-sciences-risks-responses-and-outlook https://corpgov.law.harvard.edu/2026/03/11/shareholder-activism-in-life-sciences-risks-responses-and-outlook/#respond Wed, 11 Mar 2026 11:30:36 +0000 https://corpgov.law.harvard.edu/?p=179405?d=20260310155009EDT Posted by Leonard Wood and Rob Masella, Goodwin Procter LLP, on Wednesday, March 11, 2026
Editor's Note:

Leonard Wood is Chair of the Shareholder Activism and Takeover Defense Practice, and Rob Masella is Co-Head of the Public M&A and Life Sciences M&A Groups at Goodwin Procter LLP. This post is based on their Goodwin memorandum.

Shareholder activism in the life sciences sector has intensified in recent years, with activist funds and other event-driven investors increasingly targeting companies to influence management, governance, strategy, and capital deployment. Since 2020, more than 320 public campaigns and related engagements have been initiated across life sciences and healthcare companies, driven largely by the prevalence of pre-revenue business models, binary valuation dynamics tied to clinical and regulatory inflection points, persistent trading below cash or asset value, and the susceptibility of companies in these industries to activist narratives on strategic optionality and capital allocation.

For boards and management teams, understanding the evolving activism landscape, identifying vulnerability indicators, and implementing proactive preparedness measures have become essential components of effective oversight and management. This article reviews major activism trends from 2025, analyzes the structural and market dynamics that shape life sciences campaigns, and offers practical guidance for companies preparing for activism in 2026 and beyond.

(more…)

]]> https://corpgov.law.harvard.edu/2026/03/11/shareholder-activism-in-life-sciences-risks-responses-and-outlook/feed/ 0